Last reviewed · How we verify

Bo-In Lee — Portfolio Competitive Intelligence Brief

Bo-In Lee pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Oral sulfate solution (OSS) Oral sulfate solution (OSS) marketed Osmotic laxative Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ahmed M Maged, MD · 1 shared drug class
  2. Amsterdam UMC, location VUmc · 1 shared drug class
  3. Azienda Policlinico Umberto I · 1 shared drug class
  4. Bayer · 1 shared drug class
  5. Benaroya Research Institute · 1 shared drug class
  6. Braintree Laboratories · 1 shared drug class
  7. Brooke Army Medical Center · 1 shared drug class
  8. Aboca Spa Societa' Agricola · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bo-In Lee:

Cite this brief

Drug Landscape (2026). Bo-In Lee — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bo-in-lee. Accessed 2026-05-16.

Related